-
Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
in PRESS RELEASE 2022 onFerring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle…
-
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
in PRESS RELEASE 2022 onNew subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660.
-
Panicked and overwhelmed: NEW study reveals the emotional and psychological impact of infertility
in PRESS RELEASE 2022 onNew research published in Reproductive Biomedicine, has found that 60% of people believe that the diagnosis and treatment of infertility has impacted their mental health. This impact on mental health has been found to increase with treatment duration and…
-
Gender, health and racial inequalities to be tackled in flagship Ferring grant programme
in PRESS RELEASE 2022 onForensic analysis of stone age human fertility to better understand why modern-day sperm counts are falling, and a project to support safe birth in rural Ethiopia by providing trained midwives and solar power kits, are among 17 winners of a new Ferring Pharmaceuticals…
PRESS RELEASE 2022
PRESS RELEASE 2022
